DURECT CORPORATION

Analyst Reco. DURECT Corporation Deutsche Boerse AG

Equities

DC8A

US2666055007

Market Closed - Deutsche Boerse AG Other stock markets 15:50:00 2024-07-17 EDT			5-day change	1st Jan Change
1.28 ^EUR	+6.67%		+7.56%	+143.81%

05-21	DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	CI
05-21	Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says	05-14	MT
JonesTrading Downgrades Durect to Hold From Buy	11-09	MT
HC Wainwright Downgrades Durect to Neutral From Buy	11-08	MT
Cantor Fitzgerald Adjusts Price Target on Durect to $41 From $44, Keeps Overweight Rating	23-08-10	MT
HC Wainwright Adjusts Price Target on Durect to $27 From $32, Maintains Buy Rating	23-08-10	MT
JonesTrading Initiates Durect at Buy With $37 Price Target	23-03-14	MT
HC Wainwright Trims Price Target on Durect to $32 From $35, Maintains Buy Rating	23-03-08	MT
Oppenheimer Adjusts Price Target on Durect to $32 From $6 on Reverse Stock Split, Market Conditions, Maintains Outperform Rating	22-12-07	MT
DURECT : Chardan Suspends Coverage on Durect at Buy Rating With $8 Price Target	21-08-02	MT
DURECT : Chardan Adjusts Price Target on Durect to $8 From $7, Maintains Buy Rating	21-02-03	MT
Berenberg NASH Day	19-02-25	FA
DURECT Corporation : to Participate in the Berenberg NASH Day	19-02-21	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer